Introduction
============

Perioperative acute hypoxic-ischemic cardiac toxicity of anesthetics is one of the most serious complications during surgical procedures, and occurs following the blockade of sodium channels and negative inotropic effect ([@b1-etm-0-0-8440]--[@b4-etm-0-0-8440]). To avoid cardiac toxicity, selection of a suitable drug for the maintenance of anesthesia, especially during cardiac surgery, is crucial ([@b5-etm-0-0-8440],[@b6-etm-0-0-8440]). A combination of epidural and general anesthetics have been commonly applied to reduce the use of general anesthetics, such as combining ropivacaine, a local anesthetic, and propofol, a general anesthetic ([@b7-etm-0-0-8440],[@b8-etm-0-0-8440]). Ropivacaine reportedly possesses lower cardiovascular and central nervous toxicity *in vivo*, in comparison with bupivacaine ([@b9-etm-0-0-8440],[@b10-etm-0-0-8440]). However, its underlying mechanisms remain unknown, and it is unclear whether the mechanism of action is involved in the induction of perioperative ischemic and hypoxic toxicity ([@b11-etm-0-0-8440],[@b12-etm-0-0-8440]).

In contrast, due to its phenolic structure, propofol can prevent ischemic/reperfusion injury ([@b13-etm-0-0-8440],[@b14-etm-0-0-8440]). Furthermore, propofol has an anti-oxidative effect in rat cardiomyocytes and macrophages, which is associated with the suppression of oxidative stress-related enzymes including inducible nitric oxide synthase, superoxide dismutase (SOD) and neutrophil cytosolic factor 1. In addition, propofol is associated with an increase in intracellular nitric oxide release ([@b15-etm-0-0-8440],[@b16-etm-0-0-8440]) and the preservation of Bcl2 expression levels ([@b17-etm-0-0-8440]). Propofol was shown to protect microglia from hypoxia-induced inflammation and apoptosis by maintaining intracellular Ca^2+^ homeostasis and the activation of the JNK1/Stat3 signaling pathway ([@b18-etm-0-0-8440]). Furthermore, propofol exerts antiproliferative and anti-invasive effects on hepatocellular carcinoma and rheumatoid arthritis fibroblast-like synoviocytes via the Wnt/β catenin ([@b19-etm-0-0-8440]) and NF-κB signaling pathways ([@b20-etm-0-0-8440]). Previous studies demonstrated that propofol plays a variety of roles in different cell types via various signaling pathways. However, the effects of propofol, especially when combined with ropivacaine, on human cardiomyocytes is not fully understood.

Therefore, the present study used human AC16 and HCM cardiomyocytes treated with cobalt chloride (CoCl~2~) as an *in vitro* model of cardiomyocyte ischemia. The present study investigated the signaling pathways associated with propofol and/or ropivacaine activity against oxidative stress injury in cardiomyocytes.

Materials and methods
=====================

### Cell culture

Human adult AC16 and HCM cardiomyocytes ([@b21-etm-0-0-8440]) (cat. nos. BNCC337712 and BNCC337719; Suzhou BeNa Culture Collection Biotechnology Co., Ltd.) were cultured in DMEM/F12 (Thermo Fisher Scientific, Inc.) supplemented with penicillin 100 U/ml, streptomycin 0.1 mg/ml (Invitrogen; Thermo Fisher Scientific, Inc.) and 10% FBS (Gibco; Thermo Fisher Scientific, Inc.) at 37°C in a 5% CO~2~ incubator. To establish hypoxic conditions, the cardiomyocytes were synchronized, incubated in the complete DMEM/F12 with 500 *µ*mol/l CoCl~2~ (Sigma-Aldrich; Merck KGaA; CAS Number 7791-13-1), propofol and/or ropivacaine at different concentrations for 12 h at 37°C in a 5% CO~2~ incubator.

### Cell viability assay

To select the appropriate propofol and ropivacaine concentrations, cell viability was assessed using the Cell Counting Kit-8 (CCK-8; Beyotime Institute of Biotechnology) according to the manufacturer\'s instruction. Cardiomyocytes were seeded at a density of 3×10^3^ cells in 96-well plates in sextuplicate and incubated overnight in the complete DMEM/F12 with or without 500 *µ*mol/l CoCl~2~ in an atmosphere with 5% CO~2~ at 37°C. After removing the culture medium, cells were treated with propofol (100, 50, 25, 12.5, 6.25 and 0 *µ*g/ml) or ropivacaine at different concentrations (300, 150, 75, 37.5, 18.75 and 0 *µ*g/ml in the absence of Cocl2 treatment experiments; 100, 50, 25, 12.5 and 0 *µ*g/ml in the 500 *µ*mol/l Cocl2-pretreatment experiments) in fresh medium, repeated eight times, for 48 h at 37°C. In addition, to determine the synergistic interactions between propofol and ropivacaine, AC16 and HCM cells were treated by 25 *µ*g/ml of propofol and different ropivacaine concentrations (200, 100, 50, 25, 12.5 and 0 *µ*g/ml) for 48 h at 37°C. The supernatants were discarded and the CCK-8 solution, (dilution, 1:10) was added to each well in complete DMEM/F12, and the cells were incubated for 2 h at 37°C. Absorbance at 450 nm was measured using a microplate reader (cat. no. MQX200; BioTek Instruments, Inc.). All experiments were repeated four times.

### Flow cytometry analysis

Cell apoptosis and mitochondrial membrane potential (Δψm) were evaluated using flow cytometry analysis. Cardiomyocytes were incubated in complete DMEM/F12 with or without 50 µg/ml propofol combined with 50 µM Juglanin (cat. no. 5041-67-8; HPLC ≥98%; Shanghai Zeye Biological Technology Co., Ltd.) for 2 h at 37°C, and treated with 500 µm CoCl~2~ in fresh medium for 12 h at room temperature. Following drug treatments, cells were harvested, washed twice with PBS and stained with Annexin V-FITC/PI Apoptosis Detection kit (cat. no. A211-01; Vazyme Biotech Co., Ltd.) in the binding buffer for 15 min in the dark at 25°C according to the manufacturer\'s protocol. The fluorescence intensity of Annexin V/PI-stained cells was analyzed using FACSCanto II flow cytometry (Becton, Dickinson and Company) within 1 h. Early apoptotic Annexin V^+^/PI^−^ cells were counted using FlowJo software version 7.6.1 (Tree Star, Inc.) and the quadrant percentage was considered to indicate the apoptotic ratio.

To determine the Δψm, the remaining harvested cells were incubated with JC-1 staining for 20 min at 37°C according to the manufacturer\'s protocol of a JC-1 staining kit (cat. no. KGA601; Nanjing Keygene Nanjing Kaiji Biotechnology Co., Ltd.) After washing the samples twice with the incubation buffer in this kit, cells were analyzed using the FACSCanto II flow cytometry (Becton, Dickinson and Company). These experiments were repeated three times.

### Reactive oxygen species (ROS) measurements

The effects of propofol on ROS production in CoCl~2~-treated AC16 and HCM cells were determined using a ROS-sensitive fluorescent probe (DCFH-DA) (cat. no. D6883; Sigma-Aldrich; Merck KGaA). Then, cells were analyzed using the FACSCanto II flow cytometry (Becton, Dickinson and Company). The cells were seeded at a density of 2×10^5^ cells/well into 6-well plates in triplicate in the following groups: i) Control group, with the cells cultured in complete DMEM/F12; ii) chemical hypoxia group, with the cells cultured in complete DMEM/F12 with 500 µmol/l CoCl~2~ for 12 h; and iii) propofol + chemically-induced hypoxia group, with the cells pretreated with 50 µg/ml propofol for 2 h and then exposed to chemically-induced hypoxia. After removing the culture medium, cells were washed with PBS and incubated in 10 µm DCFH-DA in fresh serum-free medium for 30--40 min in a humidified incubator at 37°C with 5% CO~2~ in the dark. Labeled cells were analyzed using FlowJo software version 7.6.1 (Tree Star, Inc.). All assays were performed in duplicate.

### SOD and malondialdehyde (MDA) detection

Total intracellular expression levels of MDA and SOD in AC16 and HCM cells were detected using commercially available kits. Cells were divided into three groups, seeded at 1×10^6^ cells/well and the following groups were analyzed: i) Control group, chemically induced hypoxia group; and ii) propofol + chemically induced hypoxia group. To detect MDA and SOD, the supernatants were removed and cells were lysed in 1 ml of cold cell lysis buffer, and then cells were crushed for 30 sec after 5 min. The lysis and further processing were repeated four times. Lysed supernatants were collected by centrifugation at 12,000 × g for 5 min at 4°C. Then, 0.25 ml of each supernatant, 1.5 ml reagent C solution and 0.3 ml reagent D were mixed (Micro-MDA Assay Reagent kit; cat. no. KGT003; Nanjing KeyGen Biotech Co., Ltd.) according to the manufacturer\'s protocol, boiled at 95°C for 40 min and then cooled in ice water for 10 min. After centrifugation at 3,000 × g for 15 min at 4°C, absorbance values were detected at 532 nm using a microplate reader. Cell lysis samples were mixed with the reagents of the Superoxide dismutase (SOD) assay kit (cat. no. KGT00150; Nanjing KeyGen Biotech Co., Ltd.) according to the manufacturer\'s instructions. Then, samples were incubated at room temperature for 10 min and the absorbance was detected at 550 nm using a microplate reader. The relative activity levels of SOD (U/ml) were calculated using the formula recommended by the supplier of the kit, and expressed according to absorbance levels. MDA and SOD concentrations were determined based on the constructed standard curve and are expressed as nmol/(mg total protein). All assays were performed in duplicate.

### Western blot analysis

Western blotting was used to evaluate the activation of the signaling pathways. Total proteins were extracted from cells that underwent different treatments using ice-cold RIPA lysis buffer (Beyotime Institute of Biotechnology) with a protease inhibitor cocktail (Roche Applied Science), and total protein concentration in every sample was determined using a BCA Protein Assay kit (Beyotime Institute of Biotechnology). Then, 40 µg of total protein solution for each sample was separated by 12% SDS-PAGE and transferred onto PVDF membrane (Bio-Rad Laboratories, Inc.). The membranes were incubated with primary antibodies against JNK1 (1:1,000; cat. no. sc-137018; Santa Cruz Biotechnology, Inc.), phosphorylated (p-)JNK (1:1,000; cat. no. sc-6254; Santa Cruz Biotechnology, Inc.), p38 (1:1,000; cat. no. 8690; Cell Signaling Technology, Inc.), p-p38 (1:1,000; cat. no. 4511; Cell Signaling Technology, Inc.) and GAPDH (1:2,000; cat. no. 5174; Cell Signaling Technology, Inc.) at 4°C overnight. Then, the membrane was incubated with a horseradish peroxidase-conjugated secondary antibody (goat anti-mouse IgG (H+L)-horseradish peroxidase (HRP) conjugate; 1:5,000; A16072SAMPLE; Thermo Fisher Scientific, Inc.; Goat anti-Rabbit IgG (H+L) Secondary Antibody-HRP; 1:5,000; Thermo Fisher Scientific, Inc.) at room temperature for 1 h. Protein bands were detected using the enhanced chemiluminescent (ECL) western blotting detection kit (cat. no. E411-03, Vazyme Biotech Co., Ltd.) and the intensity of each western blot band was quantified using Quantity One 1-D Analysis software v4.5 (Bio-Rad Laboratories, Inc.). All experiments were performed in triplicate.

### Statistical analysis

Data are presented as mean ± SD and were analyzed using one-way ANOVA followed by Tukey\'s test. All statistical analyses were performed using GraphPad Prism 4.00 (GraphPad Software, Inc.). P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Propofol increases cardiomyocyte viability and inhibits CoCl~2~-induced cytotoxicity

CCK-8 assay results suggested that cell viability significantly decreased following a 12-h incubation with increasing concentrations of CoCl~2~ (0, 125, 250, 500 or 1,000 µm; [Fig. 1A](#f1-etm-0-0-8440){ref-type="fig"}) and incubation with 500 µm CoCl~2~ for different periods (0, 6, 12, 24 and 48 h; [Fig. 1B](#f1-etm-0-0-8440){ref-type="fig"}). AC16 and HCM cell viability in the chemically induced hypoxia group was shown to decrease to 62.30% (0.7419/1.1909) and 57.13% (0.7739/1.3546), respectively, compared with the control groups following treatment with 500 µm CoCl~2~ for 12 h (P\<0.01). Therefore, these conditions were selected for further experiments.

To determine the effects of propofol and ropivacaine pretreatment on cardiomyocyte viability, the viability of AC16 and HCM cells treated with propofol or ropivacaine at different concentrations was determined using the CCK-8 assay. The present results suggested that propofol significantly increased cell viability under normal culture conditions in a dose-dependent manner ([Fig. 1C](#f1-etm-0-0-8440){ref-type="fig"}). The present results indicated that propofol could reverse the decreased viability of AC16 and HCM cells in a dose-dependent manner when combined with CoCl~2~ treatment. Moreover, the protective effects of propofol against CoCl~2~ hypoxiainduced injury were identified to be the highest at 50 µg/ml propofol ([Fig. 1D](#f1-etm-0-0-8440){ref-type="fig"}; P\<0.01). Compared with the viability observed following the application of propofol, combined propofol and ropivacaine treatment did not increase the viability of cells ([Figs. S1](#SD1-etm-0-0-8440){ref-type="supplementary-material"} and [S2](#SD1-etm-0-0-8440){ref-type="supplementary-material"}). In addition, regardless of whether the conditions were normoxic or hypoxic, ropivacaine did not affect the viability of AC16 and HCM cells ([Fig. S3](#SD1-etm-0-0-8440){ref-type="supplementary-material"}). Therefore, propofol was selected for further investigation.

### Propofol inhibits activation of the JNK signaling pathways in AC16 and HCM cells exposed to CoCl~2~

In order to identify the signaling pathways involved in the anti-apoptotic functions of propofol, the present study investigated the activation of the NF-κB and mitogen-activated protein kinase (MAPK) signaling pathways. These pathways are reported to be the key signal transduction pathways involved in CoCl~2~-induced apoptosis in BV2 and HK2 cells ([@b18-etm-0-0-8440]). However, in the present study, propofol did not affect the phosphorylation of p65 subunit, P38, ERKs and JNK in either AC16 or HCM cells ([Fig. S4](#SD1-etm-0-0-8440){ref-type="supplementary-material"}). The present study also investigated the signaling pathways that may underlie the identified propofol effects. AC16 and HCM cells were pre-incubated with propofol at different concentrations and treated with CoCl~2~. CoCl~2~ was identified to promote the phosphorylation of JNK and P38 in AC16 cells, and the phosphorylation of JNK in HCM cells following 2 h treatment, but these effects were significantly inhibited by propofol treatment ([Fig. 2](#f2-etm-0-0-8440){ref-type="fig"}). CoCl~2~ did not increase the phosphorylation of P38 in HCM cells, which may be caused by heterogeneity between cell types. The present results indicated that JNK and p38, but not ERK signaling, represented the main components of the apoptotic pathways contributing to CoCl~2~-induced apoptosis of AC16 or HCM cells.

### Propofol protects against CoCl~2~-induced cardiac cell apoptosis

CoCl~2~ has been reported to induce apoptosis of rat cardiac H9C2 cells ([@b22-etm-0-0-8440]). Therefore, the present study used Annexin V/PI staining to investigate the apoptotic ratio of AC16 and HCM cells following different treatments ([Fig. 3A](#f3-etm-0-0-8440){ref-type="fig"}). The ratio of cells in the 500 µm CoCl~2~-induced hypoxia group was higher compared with the control group (P\<0.01). This ratio was significantly reduced after 2 h pretreatment with 50 µg/ml propofol prior to the induction of hypoxia. However, the JNK activator juglanin could counteract this reduction and considerably suppressed the anti-apoptotic effects of propofol pretreatment in CoCl~2~-induced cardiac cells ([Fig. 3B](#f3-etm-0-0-8440){ref-type="fig"}).

A hypoxiainduced injury may result in reduced mitochondrial membrane potential ([@b23-etm-0-0-8440]). Therefore, the present study investigated the effects of propofol on Δψm using JC-1 staining. The present results suggested 50 µg/ml propofol significantly inhibited CoCl~2~-induced decreases in the Δψm of AC16 and HCM cells ([Fig. 3C and D](#f3-etm-0-0-8440){ref-type="fig"}). Additionally, the present results suggested that juglanin significantly counteracted the recovery effect on Δψm induced by pretreatment with propofol and promoted the reduction of Δψm induced by CoCl~2~ (P\<0.05).

### Propofol reduces CoCl~2~-induced oxidative stress in AC16 and HCM cells

Mitochondria are considered the main source of ROS in cells ([@b24-etm-0-0-8440]). Therefore, the present study investigated the mechanism underlying the propofol-induced mitochondrial protection from oxidative stress. The production of ROS was significantly increased in the CoCl~2~ group compared with the control group (P\<0.01), and this was shown to be significantly decreased following propofol pretreatment ([Fig. 4A and B](#f4-etm-0-0-8440){ref-type="fig"}). Intracellular MDA and supernatant SOD expression levels were also investigated. The present results suggested that the production of MDA was significantly increased in the CoCl~2~ group compared with the control group, whereas the SOD levels significantly decreased compared with the controls (P\<0.01; [Fig. 4C and D](#f4-etm-0-0-8440){ref-type="fig"}). These effects of CoCl~2~ significantly decreased following the application of 25 and 50 µg/ml propofol for 2 h prior to CoCl~2~ treatment (P\<0.05).

Discussion
==========

Due to its rapid onset of action and rapid recovery profile, propofol is widely used for the initiation and maintenance of general anesthesia, sedation of mechanically ventilated adults, procedural sedation and other similar purposes ([@b25-etm-0-0-8440]). However, side effects are inevitable and include irregular heart rate, low blood pressure, burning sensation at the site of injection and suppression of breathing ([@b26-etm-0-0-8440]). Combined application of epidural anesthesia, such as ropivacaine and lidocaine, may reduce the propofol doses required for the induction and maintenance of anesthesia, and further reduce its side effects in clinical practice ([@b27-etm-0-0-8440],[@b28-etm-0-0-8440]). The present study investigated the effects of propofol and/or ropivacaine on cardiomyocytes *in vitro* under normoxic or CoCl~2~-induced hypoxic conditions.

In view of the higher detection sensitivity than other tetrazolium salts such as an MTT assay, CCK-8 is widely used for determination of cell viability in cell proliferation and cytotoxicity assays ([@b29-etm-0-0-8440]). In the present study, although absorbance values were different in control groups of different cells, which may have resulted from different incubation times, cell viability in all assays was accurately assessed by CCK-8.

CoCl~2~ has been used for mimicking pathophysiological hypoxia/ischemic conditions *in vitro*, including ROS production, by activating the hypoxic signaling pathway ([@b23-etm-0-0-8440],[@b30-etm-0-0-8440]). The present results suggested that CoCl~2~ decreased the viability of AC16 and HCM cells in a dose and timedependent manner. To mimic a moderate hypoxic environment, 500 µm CoCl~2~ treatment for 12 h was selected for further experiments. The present results suggested that this treatment induced cell apoptosis and ROS and MDA production, decreased SOD production and disrupted the integrity of the mitochondrial membrane leading to a reduction of Δψm. The present results suggested that CoCl~2~ treatment may induce the continuous flux of superoxide anions and hydrogen peroxide, inducing oxidative stress in the cells, thus reducing the activity of SOD. Therefore, CoCl~2~-induced cytotoxicity was suggested to be ROS-dependent.

Propofol was previously reported to protect cells against oxidative stress induced by hydrogen peroxide ([@b31-etm-0-0-8440],[@b32-etm-0-0-8440]), oxygen glucose deprivation ([@b33-etm-0-0-8440]) and endotoxemia ([@b34-etm-0-0-8440]), and to inhibit lipid peroxidation in various experimental cell models ([@b35-etm-0-0-8440]). The present results suggested that propofol significantly increased cell viability under normal culture conditions in a concentration-dependent manner, and the protective effects of propofol pretreatment against CoCl~2~ hypoxiainduced injury were greatest at a concentration of 50 µg/ml. The present results indicated that propofol pretreatment decreased cell apoptosis, prevented impairment of mitochondrial membrane integrity, attenuated the release of ROS and MDA and reversed the CoCl~2~-induced SOD decrease. The present results suggested that propofol may exert a strong protective effect against oxidative stress-induced injury in cardiomyocytes.

The effects of propofol differ in various cell types due to the activation or inhibition of different signaling pathways ([@b36-etm-0-0-8440]). However, since ROS-dependent intrinsic apoptosis is generally mediated by MAPK ([@b37-etm-0-0-8440]), the present study examined the activation of the NF-κB and MAPK/p38/ERK/JNK signaling pathways, which have been reported to be crucial for CoCl~2~-induced apoptosis of BV2 ([@b18-etm-0-0-8440]) and HK2 cells ([@b38-etm-0-0-8440]). Following activation of the MAPK signaling cascade ERK plays an anti-apoptotic role, while JNK and p38 exert pro-apoptotic effects during apoptosis. Moreover, the activation of the JNK and p38 signaling pathways was significantly inhibited following exposure to propofol. However, propofol was not shown to affect the phosphorylation of p65, p38, ERK and JNK in AC16 and HCM cells. The effect of CoCl~2~ and propofol treatment was similar between the two cell lines but the magnitude was different, which may be caused by cellular heterogeneity. Therefore, further mechanistic studies are required to fully elucidate the effects of propofol on human cardiomyocytes in order to improve the efficacy and decrease the side effects of the application of this anesthetic during cardiac surgeries.

In conclusion, the present results suggested that pretreatment with propofol may protect human cardiac cells from chemical hypoxiainduced injury via the regulation of the JNK signaling pathways. The present results indicated that propofol may be a promising cardioprotective against a variety of oxidative stress injuries in the heart and may be a suitable drug for the maintenance of anesthesia, especially during cardiac surgery. However, it is not fully understood whether other pathways are involved in these effects; therefore, larger cohort studies are required.
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![Effects of CoCl~2~ and propofol on the viability of AC16 and HCM cardiomyocytes. (A) Treatment of AC16 and HCM cells with different CoCl~2~ concentrations for 12 h. (B) Treatment of AC16 and HCM cells with 500 *µ*m CoCl~2~ for 0, 6, 12, 24 and 48 h. (C) Cell viability following treatment with different propofol concentrations. (D) Effects of propofol on the viability of cells treated with CoCl~2~. Data are presented as the mean ± standard deviation from three independent experiments. \*P\<0.05, \*\*P\<0.01. CoCl~2~, cobalt chloride; Con, control.](etm-19-03-1864-g00){#f1-etm-0-0-8440}

![Inhibitory effects of propofol on CoCl~2~-induced activation of the JNK/MAPK signaling pathways. AC16 and HCM cells were pre-incubated with propofol at different concentrations and then treated with 500 µm CoCl~2~. (A) Western blot analyses of p-P38 and p-JNK in propofol and CoCl~2~-treated AC16 and HCM cells. (B) The ratio between the phosphorylated and total protein for JNK, P38 and ERK. Cells treated with different concentrations of propofol and CoCl~2~. \*P\<0.05. CoCl~2~, cobalt chloride; p-, phosphorylated; Con, control.](etm-19-03-1864-g01){#f2-etm-0-0-8440}

![Propofol protects cardiomyocytes against CoCl~2~-induced apoptosis. Cells were stained with Annexin VFITC/PI and the apoptotic ratio was analyzed using flow cytometry. (A) Representative analysis of the apoptotic ratio of AC16 and HCM cells. (B) Quantification of the flow cytometry results. (C) Mitochondrial membrane potential was investigated using JC-1 staining and flow cytometry analyses. Representative flow cytometry analyses of AC16 and HCM cells. (D) Quantification of the flow cytometry analyses results. Each experiment was repeated ≥3 times. Data are presented as the mean ± SD. \*P\<0.05, \*\*P\<0.01. PI, propidium iodide; CoCl~2~, cobalt chloride; Con, control.](etm-19-03-1864-g02){#f3-etm-0-0-8440}

![Propofol reduces CoCl~2~-induced oxidative stress in AC16 and HCM cells. (A) Representative flow cytometry analyses showing the apoptotic levels of propofol- and CoCl~2~-treated AC16 and HCM cells. (B) Quantification of the flow cytometry results. (C) SOD and (D) MDA expression levels following the treatment with CoCl~2~ and/or propofol. Data are presented as the mean ± SD from three independent experiments. \*P\<0.05, \*\*P\<0.01. CoCl~2~, cobalt chloride; Con, control; ROS, reactive oxygen species; SOD, superoxide dismutase; MDA, malondialdehyde.](etm-19-03-1864-g03){#f4-etm-0-0-8440}
